Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. - Wikidata - awgldk - TriplyDB

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.

http://www.wikidata.org/entity/Q43961558

about

Applications of CYP450 testing in the clinical setting Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy Pharmacogenomics and drug response in cardiovascular disorders Personalized medicine in Type 2 Diabetes A Common Susceptibility Gene for Type 2 Diabetes Is Associated with Drug Response to a DPP-4 Inhibitor: Pharmacogenomic Cohort in Okinawa Japan Glibenclamide induces collagen IV catabolism in high glucose-stimulated mesangial cells.Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.Investigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of Gujarat Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.Pharmacogenetics of Anti-Diabetes Drugs.Implications of pharmacogenetics for individualizing drug treatment and for study design.Contributions of human cytochrome P450 enzymes to glyburide metabolism.Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19 Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects.Pharmacogenetics in type 2 diabetes: potential implications for clinical practice Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide.Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite.Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects Pharmacogenetics of glucose-lowering drug treatment: a systematic review.A note on population analysis of dissolution-absorption models using the inverse Gaussian function.Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients Pharmacogenetics of oral antidiabetic drugs.Pharmacogenetics and personalized treatment of type 2 diabetes Cytochrome P450 2C9-CYP2C9.Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide.Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics.Clinical pharmacokinetics and pharmacodynamics of vildagliptin.CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.

P2860

Q24621760-B8372D55-3494-428B-B62D-C9B943794A8A Q24651117-4ED7DE64-3139-489A-B5DC-A932EE6BE41F Q24670563-2B8C9AE1-5D6F-4D5A-80D2-96084534FC34 Q26751138-41E00FAA-2740-4638-BA95-C146662EA408 Q28080752-F8CC9E85-B7BC-4B71-8A83-89D5DAFFC05D Q28171051-28B70CC3-C1A6-4E71-8F68-B37ECAF32487 Q28542708-336C5F6D-5671-4D17-9741-207713E088D3 Q28551748-576F5F0C-3FF6-4E9F-915A-12A7627EECFB Q29347062-E5C11588-65DE-4E4A-AF78-69F328D0EDFB Q30388214-FF6D3CA4-0472-44B5-B1BF-80BD1B25D9A9 Q30571118-6E1B34EC-B89D-40A8-B5A7-943E844E3310 Q31144283-4F7C52A3-0FA8-456D-A640-59463CFE76C2 Q33555327-D4F71FAC-CA9B-4951-A54C-8DF934B8BF2E Q33779389-D704A1F1-6225-44FD-9766-731B252D1987 Q33813015-5B582611-8524-48F6-9926-BE11A0541C7A Q33984240-35F50355-ADE7-4131-9DFC-CA4359402505 Q33993320-2941AB33-7A29-4417-A335-B0F89C59B366 Q34181995-6500BAAC-3008-4B69-905E-AE1F9150FE96 Q35102211-50F7DDFD-AD42-41A8-BFE8-7CA985E90288 Q35210475-3A094C87-7953-4A51-94DC-2951D58068CA Q35211432-CD2B9584-7E90-4596-948F-409D518DA1ED Q35551835-1D130773-B7A1-42F7-9C6C-ACEEE3108140 Q35594567-F561FD14-DB7A-4171-8329-7D74B67EA622 Q35825729-7FC15606-C13E-4DB8-9B2F-17243B452429 Q35840645-ECB03916-333C-4806-9BBE-2BDE8AF92A50 Q35952687-FD3E9744-5D7B-4851-AED5-11B85522F460 Q36024467-F5C05009-EA73-4173-A956-F6ED3204BCC6 Q36639493-78916138-B43B-43EB-99EF-BCABBBD9636C Q36792740-DC984A07-8EA4-4DE4-8A1F-9DF9409977D0 Q36982648-393596B5-CA02-4753-8956-942B2ABCF9C7 Q37111029-C2C96A28-7B7E-4D80-A5D7-A621A4ADF408 Q37198235-B2B6D705-CAB0-42F5-AC90-D34B4CE4DE2C Q37227417-FA58743E-3945-4BD1-AB44-B0C0F8A04594 Q37353476-ABF1FEBB-C8B4-4E05-ABB3-29205D8C5219 Q37508445-22C257A0-B533-480E-9B4E-D7080F845C98 Q37691210-C6AD70A7-5F08-4B01-905E-0CCC93E0F6A7 Q37695883-24FBE3EF-A02B-4887-89FD-64F1A26C604D Q37822185-A0AC8591-92E5-4705-9D1B-96C26CCE1BC4 Q37984567-046E1160-BC49-4A0F-8857-F67358B8AEFE Q38059889-C188F66C-4899-48FB-9B50-B2B474FF6172

P2860

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.

http://www.wikidata.org/entity/Q43961558

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Impact of CYP2C9 amino acid po ...... esponse in healthy volunteers.

@en

Impact of CYP2C9 amino acid po ...... esponse in healthy volunteers.

@nl

type

label

Impact of CYP2C9 amino acid po ...... esponse in healthy volunteers.

@en

Impact of CYP2C9 amino acid po ...... esponse in healthy volunteers.

@nl

prefLabel

Impact of CYP2C9 amino acid po ...... esponse in healthy volunteers.

@en

Impact of CYP2C9 amino acid po ...... esponse in healthy volunteers.

@nl

P1433

Q43961558-704648F7-297F-4FDA-90EF-B2ADF6B72CF6

P1476

Q43961558-45490336-66EB-493C-9D47-12BC0698BDEA

P2093

Q43961558-225E7170-DB5D-45F6-97F5-01DA487CB8C7

Q43961558-5BA1DB2D-F573-4AF4-B032-72F339E78CC1

Q43961558-BD00703A-379F-448D-BF70-74F1FE3E74EB

Q43961558-CF99F7D8-AA0E-403C-AD4C-A737082E24D2

Q43961558-DA74D998-5368-4AFC-AE30-998655D9629D

Q43961558-DD3E9151-C7FF-4422-8667-4CC802A7DBEE

Q43961558-F6461BE4-F929-41F7-B175-080E37EEB632

P304

Q43961558-E24450E1-328F-49AD-B467-29A30D4260EB

P31

Q43961558-E0AE2BD6-BEE7-48BB-AF3A-0F149DEE8922

P356

Q43961558-73C63B67-A7DB-4C69-8123-01E04E3E147D

P407

Q43961558-E7C5D7A8-A35D-41FD-B261-50C4BCE71B69

P433

Q43961558-713CB9CC-33B3-4570-ACBA-9E63FA4733AE

P478

Q43961558-79883737-A205-4CA5-9F0E-19BA9E572DEC

P577

Q43961558-CEEFD19D-0A11-4AAE-A225-B4366938547A

P698

Q43961558-090BEBE2-850E-4A2A-9DC8-9C53DDD883E3

P356

MCP.2002.122476

P1433

Clinical Pharmacology & Therapeutics

P1476

Impact of CYP2C9 amino acid po ...... esponse in healthy volunteers.

@en

P2093

Christian Meisel

http://www.w3.org/2001/XMLSchema#string

Ingolf Meineke

http://www.w3.org/2001/XMLSchema#string

Ivar Roots

http://www.w3.org/2001/XMLSchema#string

Julia Kirchheiner

http://www.w3.org/2001/XMLSchema#string

Jürgen Brockmöller

http://www.w3.org/2001/XMLSchema#string

Steffen Bauer

http://www.w3.org/2001/XMLSchema#string

Wolfgang Rohde

http://www.w3.org/2001/XMLSchema#string

P304

286-296

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1067/MCP.2002.122476

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2002-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11956512

http://www.w3.org/2001/XMLSchema#string